Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Inspire Medical Systems (INSP)

Inspire Medical Systems Q3 revenue rises 10% to $224.5 million; EPS guidance raised

Mixed Impact 4 of 5 earnings Written later

Inspire Medical Systems reported third-quarter 2025 revenue of $224.5 million, up 10%, but net income fell to $9.9 million from $18.5 million, and diluted EPS was $0.34 versus $0.60 a year earlier. The company raised its full-year 2025 diluted EPS guidance to $0.90 to $1.00 from $0.40 to $0.50 while maintaining full-year revenue guidance of $900 million to $910 million.

Key points

  • Q3 revenue was $224.5 million, up 10% from $203.2 million; U.S. revenue was $214.4 million, up 9%.
  • Net income was $9.9 million versus $18.5 million, and diluted EPS was $0.34 versus $0.60 a year earlier.
  • Full-year 2025 diluted EPS guidance raised to $0.90 to $1.00 from $0.40 to $0.50; revenue guidance maintained at $900 million to $910 million.
  • Operating expenses rose 17% to $183.1 million, and cash, cash equivalents and investments were $410.9 million at September 30, 2025.

The filing

CompanyInspire Medical Systems (INSP)
Form8-K, current report
Filed with the SECNov 3, 2025, 4:03 PM ET
Accession number0001609550-25-000052

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.